Juvenile dermatomyositis. Where are we now?

Clin Exp Rheumatol. 2022 Feb;40(2):394-403. doi: 10.55563/clinexprheumatol/56ilob. Epub 2022 Feb 7.

Abstract

Juvenile onset idiopathic inflammatory myopathy (IIM) has many similarities and distinct differences from adult-onset disease. This review will focus on recent developments in understanding and treatment of juvenile dermatomyositis (JDM), the most common disease sub-type of IIM in childhood. JDM is a systemic immune mediated vasculopathy, increasingly recognised as a group of distinct phenotypes with variable presentation and outlook. This overview will describe long-term outlook and disease course including health-related quality of life and emerging treatments.

Publication types

  • Review

MeSH terms

  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / therapy
  • Disease Progression
  • Humans
  • Myositis* / therapy
  • Quality of Life
  • Vascular Diseases*